SHALLCROSS STEVEN A 4
4 · Theriva Biologics, Inc. · Filed Dec 15, 2023
Insider Transaction Report
Form 4
SHALLCROSS STEVEN A
DirectorCEO and CFO
Transactions
- Award
Stock Options (right to buy)
2023-12-14+700,000→ 700,000 totalExercise: $0.59From: 2024-01-14Exp: 2030-12-14→ Common Stock (700,000 underlying)
Footnotes (1)
- [F1]These stock options vest pro rata on a monthly basis over 36 months.